$524.37
-0.50 (-0.10%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MDGL is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
18 interventional · 1 observational · 2 with posted results
Held by 18 tracked-famous managers (PAULSON & CO. INC., CITADEL ADVISORS LLC, Artisan Partners Limited Partnership, JANE STREET GROUP, LLC, Holocene Advisors, LP, +13 more) · FINRA short interest 4.8 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 13 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Rezdiffra Pregnancy and Lactation RegistryNCT07541469observationalPregnancy and Infant Outcomes Among Women Exposed to Rezdiffra During Pregnancy and/or Lactation | — | Recruiting | Drug: Rezdiffra | MASH - Metabolic Dysfunction-Associated Steatohepatitis | 10 | 2030-04-08 | in 1,328 d | 2026-04-21 |
| Study of Resmetirom in Children and Adolescents With MASHNCT07763015Safety and tolerability of multiple ascending doses of resmetiromNon-randomized · Open-label · Treatment | Phase 2 | Not yet recruiting | Drug: Resmetirom | MASH, MASH - Metabolic Dysfunction-Associated Steatohepatitis | 61 | Jul 2029 | ≤ 1,077 d | 2026-08-13 |
| Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASHNCT07335601Percent change from baseline in liver fat content (LFC) as assessed by MRI-PDFF at Week 28Randomized · Triple-masked · Treatment | Phase 2 | Recruiting | Drug: Resmetirom, Placebo | MASH - Metabolic Dysfunction-Associated Steatohepatitis | 120 | Aug 2028 | ≤ 743 d | 2026-07-31 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and FibrosisNCT03900429Week 52 Dual Primary Objectives: To determine the effect of 80 or 100 mg MGL-3196 vs matching placebo on liver biopsy (NASH CRN score) at Week 52 compared with BaselineRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: MGL-3196, Placebo · Procedure: Liver Biopsy | NASH - Nonalcoholic Steatohepatitis | 1,759 | Jan 2028 | ≤ 530 d | 2026-06-01 |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)NCT04951219The effect of once daily, oral administration of resmetirom on the incidence of adverse events.Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Resmetirom | Non-Alcoholic Fatty Liver Disease | 810 | Mar 2027 | ≤ 224 d | 2026-05-27 |
| A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)NCT05500222Incidence Of adjudicated Composite Clinical Outcome eventRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Resmetirom, Placebo | NASH, Cirrhosis, Liver | 845 | Dec 2026 | ≤ 134 d | 2026-07-08 |
| A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses (6 Days) of 100 mg Resmetirom in Subjects With Severe Renal Impairment and in Matched Healthy Control Subjects With Normal Renal FunctionNCT06397872Plasma pharmacokinetics - CmaxNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: 100 mg Resmetirom Tablet | Renal Impairment | 28 | 2024-09-16actual | — | 2025-10-14 |
| A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease PatientsNCT04197479The effect of once daily, oral administration of 80 or 100 mg resmetirom versus placebo on the incidence of adverse events.Randomized · Quadruple-masked · Treatment | Phase 3 | Completed | Drug: Placebo, Resmetirom | Non-Alcoholic Fatty Liver Disease | 1,343 | 2023-01-06actual | — | 2023-09-05 |
| Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple Oral Doses of MGL-3196 in Subjects With Varying Degrees of Hepatic Impairment and Healthy Matched Control SubjectsNCT04643795Plasma pharmacokinetics - CmaxNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: MGL-3196 | Hepatic Impairment, NASH - Nonalcoholic Steatohepatitis, Cirrhosis, Liver | 87 | 2021-08-04actual | — | 2023-10-05 |
| Drug Interaction Study of MGL-3196 With ClopidogrelNCT04671069AUC from the time of dosing of clopidogrel as affected by single and multiple daily dosing with MGL-3196 100 mg/day in healthy subjectsOpen-label · Treatment | Phase 1 | Completed | Drug: MGL-3196, Clopidogrel | Healthy | 20 | 2019-08-30actual | — | 2020-12-28 |
| Drug Interaction Study of MGL-3196 With PioglitazoneNCT04671056AUC from the time of dosing of pioglitazone as affected by chronic dosing with MGL-3196 100 mg/day in healthy subjectsOpen-label · Treatment | Phase 1 | Completed | Drug: MGL-3196, Pioglitazone 15mg | Healthy | 16 | 2018-12-11actual | — | 2020-12-17 |
| Bioavailability Study of MGL-3196 Tablets Compared to CapsulesNCT03413124Area under the curve from the time of dosing extrapolated to infinity (AUC(0-inf))Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: MGL-3196 Tablet, MGL-3196 Capsule | Healthy | 16 | 2018-02-17actual | — | 2019-09-18 |
| Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)NCT03038022results2025-12-23Mean Percent Change in LDL-C From Baseline To Week 12Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: MGL-3196 (resmetirom), Placebo | Heterozygous Familial Hypercholesterolemia | 116 | 2018-01-15actual | — | 2026-06-04 |
| Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH)NCT02912260results2025-12-23Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: MGL-3196, Placebo | Non-alcoholic Steatohepatitis | 125 | 2017-10-25actual | — | 2025-12-23 |
| Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196NCT03220165Mass Balance of [14C] MGL-3196Open-label · Treatment | Phase 1 | Completed | Drug: MGL-3196 | Healthy | 8 | 2017-09-03actual | — | 2017-12-19 |
| Drug Interaction Study of MGL-3196 With AtorvastatinNCT02749578Area under the curve from the time of dosing extrapolated to infinity (AUC(0-inf)) of Atorvastatin as affected by MGL-3196Open-label · Treatment | Phase 1 | Completed | Drug: Atorvastatin, MGL-3196 | Healthy | 14 | May 2016actual | — | 2016-08-30 |
| Drug Interaction Study of MGL-3196 With Rosuvastatin and SimvastatinNCT02542969Area under the curve from the time of dosing extrapolated to infinity (AUC(0-inf)) of Rosuvastatin as affected by MGL-3196Open-label · Treatment | Phase 1 | Completed | Drug: Simvastatin, Rosuvastatin, MGL-3196 | Healthy | 25 | Oct 2015actual | — | 2022-09-02 |
| Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy SubjectsNCT01519531Number of Adverse Events as a measure of safety and tolerability of VIA-3196Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Placebo, VIA-3196 | Drug Safety | 48 | Nov 2012actual | — | 2012-12-06 |
| Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy SubjectsNCT01367873Number of Adverse Events as a measure of safety and tolerability of VIA-3196Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: Placebo, VIA-3196 | Drug Safety | 72 | Oct 2011actual | — | 2023-08-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19